Patient-Derived Melanoma Organoids Preserve Tumor-Immune Heterogeneity and Reveal Context-Dependent Responses to Immune Checkpoint Blockade
Abstract Background: Experimental models that retain endogenous tumor immune complexity are needed to investigate heterogeneous responses to immune checkpoint inhibitors (ICIs) in melanoma. We established patient-derived melanoma organoids (PDMOs) to examine retention of parental tumor cellular components and investigate patient-specific and context-dependent responses to checkpoint blockade.…
Patient-derived melanoma organoids (PDMOs) successfully captured the intricate interplay between tumor and immune components, providing a valuable tool to study the diverse reactions to immune checkpoint inhibitors in melanoma patients. Researchers created PDMOs from 60% of 50 fresh melanoma specimens, preserving melanoma cells, stromal elements, lymphoid cells, and myeloid components from the original tumors.
The study explored varying responses to different checkpoint blockade therapies and oxygen levels, revealing that PDMOs and traditional two-dimensional cultures exhibited distinct sensitivities to treatment. This context-dependent sensitivity highlighted the importance of considering tumor-immune composition and environmental factors when predicting treatment outcomes.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
